📧 FREE CASE EVALUATION: info@glp1lawsuits.com

Quick Case Evaluation

Find out if you qualify in 30 seconds

Free Consultation • No Fee Unless We Win

Have You Suffered Serious Side Effects from a GLP‑1 Drug?

Drugs like Ozempic, Wegovy, and Mounjaro have helped many manage diabetes and weight — but for some, the cost has been devastating. If you've experienced stomach paralysis (gastroparesis), intestinal blockage (ileus), persistent vomiting, or other serious complications, you may be entitled to legal compensation.

1,100+ MDL Lawsuits
24,499+ Reported Cases
24h Response Time
Check Your Eligibility Now

Free Case Evaluation • No Fee Unless We Win

Confidential Consultation Experienced Legal Team Nationwide Service

Serious Health Risks from GLP-1 Medications

Thousands of patients have experienced severe complications from Ozempic, Wegovy, Mounjaro, and other GLP-1 drugs. Our legal team is dedicated to helping victims seek compensation and justice.

Free Case Evaluation

No fee unless we win your case. Free consultation available.

MDL 3094: Nationwide Lawsuits Are Underway

In February 2024, a U.S. court created MDL No. 3094, consolidating over 1,100 lawsuits against Novo Nordisk and Eli Lilly, the makers of Ozempic, Wegovy, and Mounjaro.

These lawsuits allege that:

  • The drugmakers failed to warn patients of the risk of serious gastrointestinal injuries
  • Patients suffered long-term or permanent damage, including gastroparesis, bowel obstruction, pancreatitis, and more

The cases are now moving forward in federal court under Judge Gene E.K. Pratter in Philadelphia. If you've been harmed, it's not too late to join.

Each case remains individual. The sooner you act, the better your chances of preserving your rights and medical evidence.

Critical Statistics

Recent studies and reports reveal alarming statistics about GLP-1 medication side effects.

24,499
Emergency Department Visits
10+
Deaths Reported
100+
Hospitalizations
1,100+
MDL Lawsuits

Common Side Effects Named in Lawsuits

GLP-1 medications have been linked to numerous serious health complications that can be life-altering.

Gastrointestinal Injuries

  • Gastroparesis (stomach paralysis)
  • Persistent nausea or vomiting
  • Intestinal blockage (ileus)
  • Pancreatitis

Other Potential Complications

  • Vision loss
  • Kidney dysfunction
  • Suicidal ideation or mood changes
  • Severe dehydration & malnutrition

Gastroparesis (Stomach Paralysis)

A condition where the stomach cannot empty properly, leading to severe nausea, vomiting, and abdominal pain. Many patients require surgical intervention.

Click for detailed information →

Pancreatitis

Inflammation of the pancreas that can be life-threatening. Studies show increased risk compared to other weight loss medications.

Click for detailed information →

Gallbladder Disease

Including gallstones and inflammation requiring surgical removal. Multiple patients have reported needing gallbladder removal after taking GLP-1 medications.

Click for detailed information →

Bowel Obstruction

Blockages preventing food or liquid from moving through the intestines, requiring emergency medical intervention.

Click for detailed information →

Intestinal Tissue Death

As reported in multiple cases, requiring surgical removal and permanent ileostomy. Some patients have lost parts of their large intestine.

Click for detailed information →

Kidney Problems

Including reduced kidney function and potential kidney damage, particularly concerning for long-term use.

Click for detailed information →

Optic Nerve Damage

Potential vision impairment, as alleged in recent lawsuits against manufacturers.

Click for detailed information →

Mental Health Issues

Including potential suicidal thoughts, as identified in European research and FDA monitoring.

Click for detailed information →

Legal Developments & Lawsuits

The legal landscape surrounding GLP-1 medications is rapidly evolving with multiple lawsuits filed across the country.

March 2024

Multiple Lawsuits Filed

Dozens of patients sued Eli Lilly and Novo Nordisk, claiming they suffered distressing digestive symptoms after taking the drugs. More than 60 lawsuits were centralized under a federal judge in Philadelphia.

September 2024

Severe Case: Juanita Gantt

A 62-year-old patient was hospitalized after taking Wegovy and Ozempic. Parts of her large intestine died and needed to be removed. She now lives with a permanent ileostomy bag.

October 2023

Study Links GLP-1 Drugs to Stomach Problems

Research published in JAMA found that people taking GLP-1 drugs had higher risk of pancreatitis, bowel obstruction, and gastroparesis compared to other weight loss medications.

April 2025

25,000 Emergency Department Visits

Study revealed that an estimated 24,499 people visited emergency departments for adverse events related to semaglutide in just two years following its approval.

July 2025

Optic Nerve Damage Lawsuit

A plaintiff from Illinois sued Novo Nordisk, claiming that Wegovy caused debilitating optic nerve damage, expanding litigation beyond gastrointestinal claims.

Latest News & Research

Stay informed about the latest developments and research regarding GLP-1 medications and their potential side effects.

Poison control calls surge as GLP-1 drugs gain popularity

Pennsylvania and New Jersey poison control centers described a steep rise in calls related to GLP-1 weight-loss drugs. Exposures at New Jersey's center jumped from 29 cases in 2021 to 189 in 2024.

Source: WHYY News, May 2025

Patients sue over alleged side effects of GLP-1 drugs

A TIME investigation highlights lawsuits filed by patients who experienced debilitating side effects while taking Ozempic, Wegovy, Mounjaro and other GLP-1 drugs.

Source: TIME Magazine, November 2024

Ozempic face and other GLP-1 side effects

UCLA Health explains that rapid weight loss from GLP-1 drugs can cause cosmetic changes dubbed "Ozempic face" along with digestive issues.

Source: UCLA Health, May 2025

Additional Research & Case Studies

Comprehensive research findings and detailed case studies documenting the impact of GLP-1 medications.

Study Links GLP-1 Drugs to Severe Stomach Problems

Research published in the Journal of the American Medical Association found that people taking GLP-1 drugs for weight loss had a higher risk of pancreatitis, bowel obstruction, and gastroparesis compared to those taking non-GLP-1 weight loss medications.

Source: NBC News, October 2023

Nearly 25,000 Emergency Department Visits Linked to Semaglutide

A study published in Annals of Internal Medicine revealed that an estimated 24,499 people visited emergency departments for adverse events related to semaglutide in just two years following its approval for weight loss.

Source: Healio Gastroenterology, April 2025

FDA Reports Multiple Deaths and Hospitalizations from Compounded Semaglutide

Approximately 10 deaths and 100 hospitalizations in the United States have been linked to use of off-brand, compounded semaglutide, according to the drug's manufacturer Novo Nordisk.

Source: Pharmacy Times, November 2024

Recent Developments

Latest updates and developments in GLP-1 litigation and research.

MDL Case Count Update - June 2025

There are currently 1,882 pending cases in the GLP-1 RA MDL (MDL 3094) in the Eastern District of Pennsylvania. For a litigation that only began in early 2024, that is a solid number, and filings have been steady.

The docket includes almost all gastroparesis claims. There are an increasing number of vision loss lawsuits involving NAION, but this MDL does not cover those. The MDL consolidates claims involving Ozempic, Wegovy, Mounjaro, Rybelsus, and focuses on failure to warn of serious GI and vision-related side effects.

Key Developments:

  • Rule 702 Hearing on May 14, 2025 - Admissibility of expert causation testimony
  • Defense focus on excluding expert opinions lacking gastric emptying tests
  • Discovery currently limited to FDA label adequacy and warning content
  • Plaintiffs targeting label inadequacy and misleading advertising

NAION Claims Are Heating Up - June 2025

Twenty-one New Jersey plaintiffs who say they suffered permanent vision loss after taking Ozempic or Wegovy are seeking to consolidate their lawsuits into a multicounty litigation against Novo Nordisk. They are asking New Jersey state courts to coordinate the growing number of cases involving a rare and irreversible eye condition called nonarteritic anterior ischemic optic neuropathy, or NAION.

These plaintiffs argue that centralization would streamline discovery, reduce inconsistent rulings, and make the litigation more manageable as filings continue to increase, the same arguments that got us a gastroparesis MDL.

Notable Developments:

  • NAION claims now generating more attention than gastroparesis lawsuits
  • Permanent blindness presents particularly high-stakes form of injury
  • More likely to motivate individual lawsuits, media coverage, and jury trials
  • Scientific studies continue to examine causal link between GLP-1 receptor agonists and optic nerve damage

Beyond Just NAION: Vision Loss Concerns - June 2025

A new study in JAMA Ophthalmology has added another entry to the growing ledger of concerns about Ozempic and Wegovy, with yet more concerns involving the loss of vision.

Researchers from the University of Toronto found that patients taking semaglutide, the active ingredient in both drugs, were twice as likely to develop neovascular age-related macular degeneration (nAMD). This disease gradually destroys central vision and often leads to permanent impairment.

Study Details:

  • Looked at nearly 140,000 patients with type 2 diabetes from 2020 to 2023
  • Risk was small in absolute terms, just over two in 1,000 for semaglutide users versus one in 1,000 for non-users
  • Increase was real and statistically significant
  • Researchers controlled for other known risk factors including kidney function, smoking, and use of insulin and metformin
  • Biological plausibility: GLP-1 drugs alter vascular and inflammatory pathways directly implicated in macular degeneration

New NAION Lawsuit Filed - June 2025

In a new lawsuit filed on Thursday in New Jersey Superior Court, a man from Woodbridge, New Jersey, alleges that his use of the weight-loss drug Wegovy caused him to suffer non-arteritic anterior ischemic optic neuropathy, resulting in permanent vision loss.

The lawsuit claims that the drug's manufacturers failed to adequately warn consumers and healthcare providers about the risk of NAION. The plaintiff alleges that the company knew or should have known of the potential for Wegovy to cause optic nerve damage, yet continued to market the drug without proper safety disclosures.

He is seeking compensatory and punitive damages for his injuries, ongoing medical treatment, and diminished quality of life.

NAION Warning Momentum Building - June 2025

Momentum is building behind calls for the FDA to take action on Ozempic's potential vision risks. Several ophthalmologists and public health advocates are now urging the agency to require a black box warning on semaglutide drugs, including Ozempic, Wegovy, and Rybelsus, in light of mounting evidence linking them to nonarteritic anterior ischemic optic neuropathy (NAION).

This comes after recent reports in JAMA Ophthalmology and a Danish registry study suggested a statistically significant association between semaglutide use and sudden vision loss events. The push for regulatory change is being amplified by attorneys involved in the New Jersey multicounty litigation effort, who argue that Novo Nordisk has long been aware of this potential risk but has failed to update its labeling accordingly.

A black box warning would represent a major shift in how these drugs are regulated and could significantly impact their marketability and legal liability.

Compounded Semaglutide Dangers - November 2024

Approximately 10 deaths and 100 hospitalizations in the United States have been linked to use of off-brand, compounded semaglutide (Ozempic), according to the drug's manufacturer Novo Nordisk. The report came after the company called on the FDA to prohibit compounding of semaglutide, citing significant safety concerns around the use of off-brand products.

Key Issues:

  • Novo Nordisk argued that semaglutide products should be placed on the Demonstrable Difficulties for Compounding (DDC) Lists
  • Complexities associated with formulations, delivery mechanisms, dosage forms, achievement of bioavailability
  • FDA had previously issued a letter stating there were over 350 cases of adverse events linked to use of compounded semaglutide
  • Reports indicate dosing error, higher doses than approved by the FDA, and products containing salt forms instead of base forms
  • Some facilities were selling semaglutide in combination with BPC-157, which has been prohibited by the FDA

Resources & Information

Access important information and resources related to GLP-1 medications and their potential side effects.

Understanding Your Rights

If you or a loved one has experienced serious side effects from GLP-1 medications, you may have legal rights to compensation. Our legal team specializes in pharmaceutical litigation and can help you understand your options.

  • Free Case Evaluation: We offer confidential consultations to assess your case
  • No Upfront Costs: We work on a contingency fee basis - you only pay if we win
  • Nationwide Representation: We serve clients across the United States
  • Experienced Attorneys: Our team has successfully handled pharmaceutical litigation cases

Common Questions About GLP-1 Lawsuits

Q: What types of side effects qualify for a lawsuit?

A: Serious side effects that may qualify include gastroparesis, pancreatitis, gallbladder disease, bowel obstruction, intestinal tissue death, kidney problems, optic nerve damage, and mental health issues.

Q: How long do I have to file a lawsuit?

A: The time limit varies by state, typically 1-3 years from when you discovered or should have discovered your injury. It's important to consult with an attorney as soon as possible.

Q: What compensation might be available?

A: Potential compensation may include medical expenses, lost wages, pain and suffering, and punitive damages in some cases.

Q: Do I need to stop taking my medication?

A: You should consult with your healthcare provider before making any changes to your medication regimen. We can help you understand the risks and benefits.

What You Can Do

Document your symptoms and diagnosis

Keep detailed records of all medical visits, symptoms, and treatments

Gather your medication history

Save all medication bottles, prescriptions, and medical records

Get a free legal evaluation

Understand your rights and potential compensation options

Don't wait. You may be eligible for compensation — but deadlines may apply.

Check Your Eligibility Now

Free Case Evaluation • No Fee Unless We Win

Current Legal Developments

The legal landscape surrounding GLP-1 medications is rapidly evolving:

  • MDL Consolidation: Over 1,800 cases have been consolidated in federal court
  • New Jersey Litigation: 21 plaintiffs seeking multicounty litigation for vision loss claims
  • FDA Investigations: Ongoing monitoring of adverse event reports
  • Class Action Potential: Cases may be eligible for class action status

Support Resources

If you're dealing with GLP-1 medication side effects, these resources may help:

  • Medical Support: Connect with specialists who understand GLP-1 complications
  • Patient Communities: Online support groups for those affected
  • Mental Health Resources: Counseling and support for depression and anxiety
  • Financial Assistance: Programs to help with medical expenses
  • Legal Guidance: Our team can help you understand your legal options

About Our Legal Team

We are a North American law firm devoted to holding pharmaceutical companies accountable when their products cause harm. With extensive experience litigating cases involving dangerous drugs, our attorneys are committed to seeking justice for people who have suffered injuries or illnesses after taking GLP-1 medications.

Our legal team understands the complex medical and regulatory issues surrounding weight‑loss and diabetes drugs. We collaborate with medical experts to investigate side effects and build strong cases. If you or a loved one has experienced severe nausea, vomiting, gastrointestinal problems or other complications after taking Ozempic, Wegovy, Mounjaro, Zepbound or similar medications, we are here to help.

Our Commitment

We provide compassionate guidance, thorough case evaluation and vigorous representation to help clients obtain compensation and support for their injuries and medical expenses.

Get Your Free Case Evaluation

If you have been affected by GLP-1 medications, our legal team is ready to help. Take the first step towards justice today.

Start Your Free Case Review →
No fee unless we win your case. Confidential consultation — response within one business day.